New vaccine trial aims to protect african babies from severe diarrhea
NCT ID NCT06663436
Summary
This study tested whether a 2-dose schedule of an experimental Shigella vaccine is safe and triggers a protective immune response in African infants. The trial involved 200 healthy 9-month-old babies in Kenya. Researchers measured antibody levels and monitored for side effects to determine if this simpler dosing could help prevent shigellosis, a serious diarrheal disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Kericho, 20200, Kenya
Conditions
Explore the condition pages connected to this study.